A Bridging study to Evaluate the Effects of LODONAL as an Immune-System Regulating Agent in Subjects in Which their Immune System is Compromised

Trial Profile

A Bridging study to Evaluate the Effects of LODONAL as an Immune-System Regulating Agent in Subjects in Which their Immune System is Compromised

Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2017

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Acquired immunodeficiency syndrome; HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Immune Therapeutics
  • Most Recent Events

    • 31 May 2017 According to an Immune Therapeutics media release, the company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines. The application will include results of four phase II clinical trials and one bridging trial clinical trial.
    • 27 Apr 2016 Status changed from recruiting to completed, as per as per Immune Therapeutics media release.
    • 27 Apr 2016 According to Immune Therapeutics media release, Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) has approved its patented Lodonal as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune system regulator.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top